Analyst: Zealand Pharma pipeline will be crucial

US-based investment bank Jefferies puts most stock in Zealand Pharma’s phase III trial of glepaglutide, a potential treatment for short bowel syndrome, when it comes to the company’s future plans.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR
by marketwire, translated by daniel pedersen

The potential of Zealand Pharma’s drug pipeline has been overlooked, according US-based investment bank Jefferies, which maintains its ”buy” recommendation for the biotech company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading